David Navratil, MD
Clinical Cardiac Electrophysiology · Las Vegas, NVNPI 1043267024
Payments from drug & device makers
Across 505 payments — averaging $58.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$10K
- Medtronic$4K
- Atricure, Inc.$4K
- Abbott$2K
- Elutia, Inc.$2K
- Novartis$833
- plus $7K from 33 others
What the payments were for
- Travel & lodging$7,98827%
- Food & beverage$21,20372%
- Education$1821%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 125 | $9,649 |
| Medtronic(2 entities) | 42 | $4,098 |
| Atricure, Inc. | 24 | $3,812 |
| Abbott | 26 | $2,325 |
| Elutia, Inc. | 12 | $1,713 |
| Novartis | 43 | $833 |
| Johnson & Johnson(2 entities) | 49 | $790 |
| Philips North America LLC | 3 | $788 |
| E.r. Squibb & Sons, L.L.C. | 36 | $642 |
| ZOLL Respicardia, Inc. | 4 | $612 |
| Cvrx, Inc. | 9 | $610 |
| Merck | 27 | $556 |
| Cook Medical LLC | 5 | $357 |
| Kestra Medical Technology Services, Inc. | 5 | $279 |
| Amgen | 13 | $249 |
| Boehringer Ingelheim | 10 | $229 |
| Bayer | 11 | $201 |
| Novo Nordisk | 9 | $196 |
| Astellas Pharma US Inc | 4 | $196 |
| Sanofi-aventis U.S. LLC | 8 | $150 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $146 |
| W. L. Gore & Associates, Inc. | 3 | $124 |
| Vital Connect, Inc | 1 | $101 |
| Alnylam Pharmaceuticals Inc. | 4 | $93 |
| Biosense Webster, Inc. | 1 | $92 |
| Abiomed | 2 | $91 |
| Actelion Pharmaceuticals US, Inc. | 3 | $72 |
| Bridgebio Pharma, Inc. | 2 | $63 |
| Pfizer | 3 | $50 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $36 |
| Lexicon Pharmaceuticals, Inc. | 2 | $35 |
| Preventice Services, LLC | 1 | $34 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $28 |
| Davol Inc. | 1 | $27 |
| Medicomp Inc | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $13 |
| Convatec Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$3,027
- GENERAL - THERAPIES$2,940
- Farapulse$2,295
- ECM Patch,Pouch$1,643
- Micra$1,514
- ATRICLIP LAA EXCLUSION SYSTEM$821
- (9520) IGT Devices Undivided$726
- CARDIOMEMS$611
- remede System$595
- EP-WorkMate Claris System$343
- Barostim Neo System$338
- QUADRA ASSURA$327
- AZURE XT DR MRI SURESCAN$297
- AURORA EV-ICD MRI SURESCAN$273
- Cobalt$267
- RESONATE$186
- SelectSecure$173
- CardioMEMS HF System$168
- Intrinsic$151
- Attain$147
How this compares
$29,373 in reported general payments places this provider in the 60th percentile of 20 clinical cardiac electrophysiology providers in Nevada.
See all clinical cardiac electrophysiology providers in Nevada →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 143 | $170,993 |
| EntrestoSacubitril/Valsartan | 68 | $79,959 |
| XareltoRivaroxaban | 50 | $58,673 |
| MultaqDronedarone Hcl | 28 | $52,286 |
| Propafenone Hcl ErPropafenone Hcl | 14 | $3,945 |
| Flecainide Acetate | 71 | $2,723 |
| Amiodarone Hcl | 109 | $2,478 |
| Metoprolol Succinate | 176 | $2,366 |
| Digoxin | 77 | $2,124 |
| Verapamil ErVerapamil Hcl | 48 | $2,083 |
| Nebivolol Hcl | 29 | $2,029 |
| Dofetilide | 24 | $1,727 |
| Verapamil SrVerapamil Hcl | 23 | $1,689 |
| Propafenone Hcl | 30 | $1,524 |
| Acebutolol Hcl | 27 | $1,469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $50 | $170,993143 claims |
| NovartisEntresto | $833 | $79,95968 claims |
| Johnson & JohnsonXarelto | $790 | $58,67350 claims |
| Sanofi-aventis U.S. LLCMultaq | $150 | $52,28628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 20 clinical cardiac electrophysiology providers in Nevada.
Other clinical cardiac electrophysiology in Las Vegas
- Claudio BonomettiLas Vegas$91K
- Dhiraj NarulaLas Vegas$63K
- Erik SirulnickLas Vegas$54K
- Niuton KoideLas Vegas$43K
- Khawaja BaigLas Vegas$21K
- Santosh RaneLas Vegas$11K
- Gaston VergaraLas Vegas$11K
- Subhasree PanchangamLas Vegas$4K
- Daejoon AnhHenderson$44K
- Juan Rodriguez ReyesSparks$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.